Molecular and Clinical Implications of Somatostatin Receptor Profile and Somatostatin Analogues Treatment in Oral Cavity Squamous Cell Carcinoma.
biomarkers
head and neck
oral cavity cancer
somatostatin analogues
somatostatin receptors
therapeutic tool
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
27 Sep 2021
27 Sep 2021
Historique:
received:
03
08
2021
revised:
02
09
2021
accepted:
22
09
2021
entrez:
13
10
2021
pubmed:
14
10
2021
medline:
14
10
2021
Statut:
epublish
Résumé
Oral squamous cell carcinoma (OSCC) incidence has increased by 50% over the last decade. Unfortunately, surgery and adjuvant radiotherapy and chemotherapy are still the mainstream modality of treatment, underscoring the need for alternative therapies. Somatostatin-analogues (SSA) are efficacious and safe treatments for a variety of tumors, but the presence of somatostatin-receptors (SSTs) and pharmacological effects of SSA on OSCC are poorly known. In this study, we demonstrated that SST
Identifiants
pubmed: 34638313
pii: cancers13194828
doi: 10.3390/cancers13194828
pmc: PMC8508167
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Ministerio de Ciencia e Innovación
ID : PID2019-105564RB-I00
Organisme : Instituto de Salud Carlos III
ID : ERDF/ESF, "Investing in your future"
Organisme : Instituto de Salud Carlos III
ID : FI17/00282
Organisme : Consejería de Economía, Innovación, Ciencia y Empleo, Junta de Andalucía
ID : P20_00442
Organisme : Ministerio de Sanidad, Servicios Sociales e Igualdad
ID : CIBERobn
Références
J Contemp Dent Pract. 2021 Apr 1;22(4):435-451
pubmed: 34267015
J Laryngol Otol. 2012 Dec;126(12):1261-70
pubmed: 23050666
Cancer Med. 2019 Sep;8(12):5810-5819
pubmed: 31400079
Minerva Endocrinol. 2019 Jun;44(2):109-128
pubmed: 30650942
CA Cancer J Clin. 2020 Jan;70(1):7-30
pubmed: 31912902
Crit Rev Oncol Hematol. 2008 Apr;66(1):1-9
pubmed: 17913510
Lung Cancer. 2017 Jul;109:128-136
pubmed: 28577942
Front Neuroendocrinol. 2013 Aug;34(3):228-52
pubmed: 23872332
BMC Oral Health. 2008 Sep 02;8:25
pubmed: 18764952
Clin Otolaryngol Allied Sci. 2003 Aug;28(4):314-9
pubmed: 12871244
Braz J Otorhinolaryngol. 2015 Jul-Aug;81(4):416-21
pubmed: 26141206
J Clin Endocrinol Metab. 2009 Jun;94(6):1931-7
pubmed: 19293270
Tumour Biol. 2006;27(1):8-16
pubmed: 16340245
CA Cancer J Clin. 2015 Sep-Oct;65(5):401-21
pubmed: 26215712
FASEB J. 2017 Nov;31(11):4682-4696
pubmed: 28705809
Trends Pharmacol Sci. 1995 Mar;16(3):110-5
pubmed: 7792931
Head Neck. 2020 Feb;42(2):238-243
pubmed: 31647162
CA Cancer J Clin. 2017 Mar;67(2):122-137
pubmed: 28128848
Eur Arch Otorhinolaryngol. 2008 Jul;265 Suppl 1:S63-7
pubmed: 18066572
Endocrine. 2018 Feb;59(2):426-437
pubmed: 29196939
J Clin Endocrinol Metab. 2019 Aug 1;104(8):3501-3513
pubmed: 30860580
Oral Oncol. 2014 Jul;50(7):651-6
pubmed: 24731736
Drugs. 2019 Jan;79(1):21-42
pubmed: 30560479
Cancer Metastasis Rev. 2011 Mar;30 Suppl 1:9-17
pubmed: 21369878
Am J Physiol Endocrinol Metab. 2009 Nov;297(5):E1078-88
pubmed: 19706788
Cancer Lett. 2015 Apr 10;359(2):299-306
pubmed: 25637790
J Clin Endocrinol Metab. 2013 Oct;98(10):4160-9
pubmed: 23884782
Int J Immunopathol Pharmacol. 2011 Apr-Jun;24(2 Suppl):113-20
pubmed: 21781456
Clin Cancer Res. 2020 Feb 15;26(4):957-969
pubmed: 31624102
J Endocrinol. 2016 Nov;231(2):135-145
pubmed: 27587848
Transl Res. 2019 Sep;211:147-160
pubmed: 30904441
Toxins (Basel). 2015 Aug 05;7(8):2959-84
pubmed: 26251921
Int J Cancer. 2019 Apr 15;144(8):1941-1953
pubmed: 30350310
Sci Rep. 2018 Apr 18;8(1):6173
pubmed: 29670116
Science. 1973 Jan 5;179(4068):77-9
pubmed: 4682131
CA Cancer J Clin. 2002 Jul-Aug;52(4):195-215
pubmed: 12139232
Prostate. 2017 Nov;77(15):1499-1511
pubmed: 28905400
Brain. 2020 Dec 5;143(11):3273-3293
pubmed: 33141183
Neuroendocrinology. 2009;90(2):184-9
pubmed: 19713709
Biochim Biophys Acta. 2003 Sep 22;1616(1):1-84
pubmed: 14507421
Eur J Endocrinol. 2007 Jan;156(1):65-74
pubmed: 17218727
Head Neck. 2019 Sep;41(9):2991-3001
pubmed: 31012518